In situ hybridization detection kit for early uterine cancer

A detection kit and in situ hybridization technology, applied in the field of kits, can solve problems such as unreported detection technology, and achieve the effects of high sensitivity, convenient operation and strong specificity

Active Publication Date: 2011-12-21
台州和和生物科技有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report about the in situ hybridization detection kit and detection technology of P2RX7 gene

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • In situ hybridization detection kit for early uterine cancer
  • In situ hybridization detection kit for early uterine cancer
  • In situ hybridization detection kit for early uterine cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] An in situ hybridization detection kit for early uterine cancer, comprising a hybridization probe, a marker, and a potentiator, wherein the sequence of the hybridization probe is shown in SEQ ID NO.1. Hybridization probes were labeled with digoxigenin. The composition of other liquids and specimens in the kit is as follows:

[0043] Digestive solution 100μl / tube 1 tube / box Colorless transparent liquid

[0044] Protective solution 100μl / tube 1 tube / box Colorless transparent liquid

[0045] Pre-hybridization solution 1300μl / tube 2 tubes / box Colorless transparent liquid

[0046] Sense hybridization solution 10μl / tube 1 tube / box Colorless transparent liquid

[0047] Antisense hybridization solution 10μl / tube 1 tube / box Colorless transparent liquid

[0048] Blocking solution 1000μl / tube 1 tube / box Colorless transparent liquid

[0049] Alkaline phosphatase antibody 1μl / tube 1 tube / box Colorless transparent liquid

[0050] Chromogen A 175μl / tube 1 tube / box Yellow liquid ...

Embodiment 2

[0093] A P2RX7 gene in situ hybridization detection method and kit application

[0094] 1. Specimen processing

[0095] 1. Use a 10ml centrifuge tube to fill 4.5ml of lymphocyte separation solution, then slowly add 3ml of anticoagulated blood into the centrifuge tube containing lymphocyte separation solution (blood: lymphocyte separation solution = 1:1.5), and centrifuge at 2000r / min 10min;

[0096] 2. Take the white blood cells in the middle layer into another centrifuge tube, then add about twice the amount of 1× buffer I to this tube, mix well, and centrifuge at 1500g / min for 10min;

[0097] 3. Discard the supernatant. Add about twice the 1× buffer I to the precipitate, mix well, and centrifuge at 1500g / min for 10min;

[0098] 4. Discard the supernatant, and absorb the excess liquid from the mouth of the test tube with paper towels. Then the precipitate was made into a suspension, dropped on a glass slide, and allowed to dry naturally. (Hospitals with conditions can use...

Embodiment 3

[0133] A comparative experiment between the detection of uterine cancer with the P2RX7 gene kit and the detection of uterine cancer with the HCCR gene kit.

[0134] In order to scientifically evaluate the specificity, sensitivity and accuracy of the above genes in uterine cancer. We use the method of parallel experiment, detect the mRNA of above-mentioned gene at the same time, detection technology adopts nucleic acid in situ hybridization technology, use the peripheral blood of patient with same uterine cancer disease, detect the mRNA of P2RX7 gene and HCCR gene at the same time (carry out nucleic acid in situ hybridization, Immunohistochemical staining, microscopic counting, result reporting, etc. all used the same methods, steps and reagents as the in situ hybridization technique in Example 1 and Example 2). It was found that the expression level of P2RX7 gene in patients with uterine cancer was higher than that of HCCR gene in patients with the same disease. The results s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an in situ hybridization detection kit for early uterine cancer, comprising a hybridization probe and a marker, and the sequence of the hybridization probe is shown in SEQ ID NO.1. The invention also provides an in situ hybridization detection method of the P2RX7 gene. In addition, the present invention also provides the application of the kit in the preparation of drugs for detecting uterine cancer. The invention has the advantages that: the kit provided by the invention has the characteristics of high sensitivity and strong specificity. The detection method of the invention is convenient and simple to operate, and can be widely used and popularized in hospitals above the district level.

Description

【Technical field】 [0001] The invention relates to a reagent kit, in particular to an in situ hybridization detection reagent kit for early uterine cancer, a detection method and application. 【Background technique】 [0002] According to the information provided by authoritative organizations at home and abroad, there are 1.6 million new cancer cases in my country every year, nearly 1.6 million deaths, and 6 million patients. Globally, there are 8 million new cancer patients every year, nearly 8 million deaths, and about 84 million patients. , by 2020 the number of people will double, which is a set of terrible figures. Uterine cancer is a malignant tumor that seriously endangers women's health. In recent years, the incidence has been steadily increasing and tends to be younger. Uterine tumors are one of the common gynecological malignancies, and the incidence rate ranks second among female tumors. According to worldwide statistics, an estimated 466,000 cases of cervical tumor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/68
Inventor 裘建英张云福
Owner 台州和和生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products